Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is the most common primary malignancy of bone in children, adolescents, and adults. Despite extensive surgery and adjuvant aggressive high-dose systemic chemotherapy with potentially severe bystander side effects, cure is attainable in about 70% of patients with localized disease and only 20%–30% of those patients with metastatic disease. Targeted therapies clearly are warranted in improving our treatment of this adolescent killer. However, a lack of osteosarcoma-associated/specific markers has hindered development of targeted therapeutics. We describe a novel osteosarcoma-associated cell surface antigen, ALCAM. We, then, create an engineered anti-ALCAM-hybrid polymerized liposomal nanoparticle immunoconjugate (α-AL-HPLN) to specifically target osteosarcoma cells and deliver a cytotoxic chemotherapeutic agent, doxorubicin. We have demonstrated thatα-AL-HPLNs have significantly enhanced cytotoxicity over untargeted HPLNs and over a conventional liposomal doxorubicin formulation. In this way,α-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study demonstrated that ALCAM was associated with tumorigenesis in osteosarcoma [111].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [111]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647 · cited 1×
“Finally from a potential therapeutic delivery perspective, it is best when candidate tumor markers are internalized when bound by ligands or proteins at the cell surface [8].”
BackgroundLipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to Clinic
Puri, A., Loomis, K., Smith, B., Lee, J.-H., Yavlovich, A., Heldman, E., & Blumenthal, R. (2009) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v26.i6.10 · Cited by 1,069 · cited 1×
“Liposomes, unilamellar vesicles composed of natural and/or synthetic lipids, have been a particularly intensively studied system [5].”
BackgroundHaran, G., Cohen, R., Bar, L. K., & Barenholz, Y. (1993) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(93)90105-9 · Cited by 934 · cited 1×
“Using this formulation, HPLNs were fabricated and their ability to be actively loaded with doxorubicin through generation of an ion gradient was assessed [21].”
MethodDetection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
Sipkins, D. A., Cheresh, D. A., Kazemi, M. R., Nevin, L. M., Bednarski, M. D., & Li, K. C. P. (1998) · Nature Medicine · doi:10.1038/nm0598-623 · Cited by 850 · cited 1×
“The use of diacetylene containing lipids to create polymerizable films and vesicles has been intensively studied for creating biosensors [25] and have been explored as cancer diagnostic and delivery vehicles [26].”
BackgroundAndresen, T. L., Jensen, S. S., & Jørgensen, K. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.12.001 · Cited by 580 · cited 1×
“This latter attribute has been particularly difficult to program into standard liposome formulations [6, 7].”
BackgroundSwart, G. W. M. (2002) · European Journal of Cell Biology · doi:10.1078/0171-9335-00256 · Cited by 251 · cited 1×
“This glycoprotein is a member of the immunoglobulin superfamily and is thought to mediate important cell-cell interactions involved in cell migration, neurogenesis, hematopoiesis, and the immune response [9].”
BackgroundOsteosarcoma of bone and its important recognizable varieties
Dahlin, D. C., & Unni, K. K. (1977) · The American Journal of Surgical Pathology · doi:10.1097/00000478-197701010-00007 · Cited by 234 · cited 1×
“This suggested that at the time of their initial diagnosis clinically undetectable tumor had already spread to distant sites in most patients and that effective systemic anticancer therapy was needed [2].”
BackgroundSequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
Janeway, K. A., & Grier, H. E. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70062-0 · Cited by 234 · cited 1×
“It is also now appreciated that exposure of pediatric cancer patients to cytotoxic chemotherapy can lead to secondary malignancies and other medical maladies, decades after their tumor has been eradicated [4].”
BackgroundIshida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., & Allen, T. M. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00409-6 · Cited by 216 · cited 1×
“The roughly 50-fold difference in IC50 between free doxorubicin and conventional liposomal doxorubicin seen in our osteosarcoma cell lines is consistent with that found in previously published model systems [22].”
Resultvan Kempen, L. C. L. T., van den Oord, J. J., van Muijen, G. N. P., Weidle, U. H., Bloemers, H. P. J., & Swart, G. W. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64943-7 · Cited by 204 · cited 1×
“For example, an increase in ALCAM expression is found in higher-stage more aggressive malignant melanoma [24].”
BackgroundKristiansen, G., Pilarsky, C., Wissmann, C., Stephan, C., Weissbach, L., Loy, V., Loening, S., Dietel, M., & Rosenthal, A. (2003) · The Prostate · doi:10.1002/pros.10161 · Cited by 136 · cited 1×
“By contrast, high ALCAM is correlated with low-grade less aggressive cases of prostate cancer [11].”
BackgroundActivated leukocyte cell adhesion molecule: a new paradox in cancer
Ofori-Acquah, S. F., & KING, J. A. C. (2007) · Translational research · doi:10.1016/j.trsl.2007.09.006 · Cited by 132 · cited 1×
“Hindawi Publishing Corporation Sarcoma Volume 2012, Article ID 126906, 11 pages doi:10.1155/2012/126906”
BackgroundInfluentialYavlovich, A., Singh, A., Blumenthal, R., & Puri, A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.07.030 · Cited by 127 · cited 1×
“Recently, others have used mixtures of diacetylene lipids and phospholipids to create liposomes that could be selectively destabilized either by photochemical means or by thermal shock [28, 29].”
MethodActivated leukocyte cell adhesion molecule in breast cancer: prognostic indicator
KING, J. A. C., Ofori-Acquah, S. F., Stevens, T., Al‐Mehdi, A. B., Fodstad, Ø., & Jiang, W. G. (2004) · Breast Cancer Research · doi:10.1186/bcr815 · Cited by 126 · cited 1×
“Hindawi Publishing Corporation Sarcoma Volume 2012, Article ID 126906, 11 pages doi:10.1155/2012/126906”
BackgroundInfluentialFluorescence of polymerized diacetylene bilayer films
Olmsted, J., & Strand, M. (1983) · The Journal of Physical Chemistry · doi:10.1021/j150642a006 · Cited by 92 · cited 1×
“Ultraviolet irradiation leads to cross-linking of diacetylene residues present in their acyl chains, leading to highly colored blue particles, and heat treatment of the PLNs and HPLN vesicles leads to color change and fluorophore formation [16, 17].”
BackgroundFactors affecting drug release from liposomes.
Lindner, L. H., & Hossann, M. (2010) · PubMed · Cited by 85
Effects of substituent-induced strain on the electronic structure of polydiacetylenes
Eckhardt, H., Boudreaux, D. S., & Chance, R. R. (1986) · The Journal of Chemical Physics · doi:10.1063/1.450882 · Cited by 85 · cited 2×
“When exposed to physiochemical perturbations such as heat, shear, or pH stress, these membranes shift from a blue nonfluorescent state to a red fluorescent state [17].”
BackgroundRoth, A., Drummond, D. C., Conrad, F., Hayes, M. E., Kirpotin, D. B., Benz, C. C., Marks, J. D., & Liu, B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0140 · Cited by 80 · cited 1×
“Furthermore, others have found that immunoliposomes coated with a recombinant anti-ALCAM monoclonal antibody were taken up by prostate cancer cell lines expressing this antigen [13].”
BackgroundSelf-citationQin, G., Li, Z., Xia, R., Li, F., O’Neill, B. E., Goodwin, J. T., Khant, H. A., Chiu, W., & Li, K. C. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/15/155605 · Cited by 76 · cited 1×
“Recently, others have used mixtures of diacetylene lipids and phospholipids to create liposomes that could be selectively destabilized either by photochemical means or by thermal shock [28, 29].”
MethodMolecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS
Nelissen, J. M. D. T., Torensma, R., Pluyter, M., Adema, G. J., Raymakers, R. A. P., van Kooyk, Y., & Figdor, C. G. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00127-2 · Cited by 73 · cited 1×
“A molecular survey of the osteosarcoma cell line U2-OS demonstrated expression of ALCAM on the surface of these cells [15].”
Backgroundde Menezes, D. E. L., Kirchmeier, M. J., Gagné, J.-F., Pilarski, L. M., & Allen, T. M. (1999) · Journal of Liposome Research · doi:10.3109/08982109909024786 · Cited by 69 · cited 1×
“Others have shown that this is primarily due to delayed release of free drug from the endocytic compartment of cells that have taken up liposomal doxorubicin [30].”
BackgroundBruehl, R. E., Dasgupta, F., Katsumoto, T. R., Tan, J. H., Bertozzi, C. R., Spevak, W. R., Ahn, D. J., Rosen, S. D., & Nagy, J. O. (2001) · Biochemistry · doi:10.1021/bi002921s · Cited by 62
Self-citationCys-diabody Quantum Dot Conjugates (ImmunoQdots) for Cancer Marker Detection
Barat, B., Sirk, S. J., McCabe, K. E., Li, J., Lepin, E. J., Remenyi, R., Koh, A. L., Olafsen, T., Gambhir, S. S., Weiss, S., et al. (2009) · Bioconjugate Chemistry · doi:10.1021/bc800421f · Cited by 61 · cited 1×
“The resulting cys-diabody is bivalent, compact (one-third the size of an intact antibody) and enables sitespecific oriented coupling of the antibody variable regions to the surface of nanoparticles [20].”
BackgroundSelf-citationGomes, C. M. F., Paassen, H. V., Romeo, S. O., Welling, M. M., Feitsma, R. I. J., Abrunhosa, A., Botelho, M. F., Hogendoorn, P. C. W., Pauwels, E. K. J., & Cleton-Jansen, A. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.07.011 · Cited by 50 · cited 1×
“The MNNGHOS cell line has high expression levels of the multidrug resistant protein 1 (MDR1) conferring chemotherapeutic resistance to doxorubicin [32].”
BackgroundRecombinant full-length human IgG1s targeting hormone-refractory prostate cancer
Liu, B., Conrad, F., Roth, A., Drummond, D. C., Simko, J. P., & Marks, J. D. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0208-z · Cited by 39 · cited 1×
“A bivalent antiALCAM diabody, derived from a previously described scFv [18], was genetically engineered to contain a C-terminal cysteine [19].”
BackgroundSelf-citationPolydiacetylene vesicles as a novel drug sustained-release system
Guo, C., Liu, S., Dai, Z., Jiang, C., & Li, W. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.10.009 · Cited by 31 · cited 1×
“Others have been able to passively load hybrid liposomes composed of a 1 : 1 mixture of a phosphatidylcholine derivative with a dichain diacetylene lipid and another phospholipid [27].”
BackgroundBowen, M. A., & Aruffo, A. A. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01773-4 · Cited by 27 · cited 1×
“The normal physiologic roles of ALCAM are still coming to light, but its molecular structure and clustering at tight junctions suggest that it could be involved in cell adhesion and migration [23].”
BackgroundMcCabe, K. E., Liu, B., Marks, J. D., Tomlinson, J. S., Wu, H., & Wu, A. M. (2011) · Molecular Imaging and Biology · doi:10.1007/s11307-011-0500-8 · Cited by 24 · cited 2×
“A bivalent antiALCAM diabody, derived from a previously described scFv [18], was genetically engineered to contain a C-terminal cysteine [19].”
BackgroundMethodSelf-citationPhase Separation and Fractal Domain Formation in Phospholipid/Diacetylene-Supported Lipid Bilayers
Moran-Mirabal, J. M., Aubrecht, D. M., & Craighead, H. G. (2007) · Langmuir · doi:10.1021/la701371f · Cited by 17 · cited 1×
“Evidence found in published studies with similar mixtures of longer chain diacetylene lipids and shorter chain phosphatidylcholine lipids suggests that a phase separation occurs between the lipid types [31].”
ResultCabral, E. C., Hennies, P. D. T., Correia, C. R. D., Zollner, R. D. L., & Santana, M. H. A. (2003) · Journal of Liposome Research · doi:10.1081/lpr-120026387 · Cited by 8 · cited 1×
“The use of diacetylene containing lipids to create polymerizable films and vesicles has been intensively studied for creating biosensors [25] and have been explored as cancer diagnostic and delivery vehicles [26].”
Background
Research works printed but not linked: 2
- Huvos AG Bone Tumors: Diagnosis, Treatment, and Prognosis 1991 Philadelphia, Pa, USA WB Saunders
- Gurney JG Swensen AR Bulterys M Malignant bone tumors Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995 1999 Bethesda, Md, USA SEER program, National Cancer Institute 99 110
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“The study demonstrated that ALCAM was associated with tumorigenesis in osteosarcoma [111].”
BackgroundNanotechnology in the targeted drug delivery for bone diseases and bone regeneration
Gu, Wu, Chen, & Xiao, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44393 · Cited by 212
“nanoparticles, and over a conventional liposomal DXR formulation.(45) Besides, magnetic arsenic trioxide NPs were”
Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications
Madni, A., Sarfraz, M., Rehman, M., Ahmad, M., Akhtar, N., Ahmad, S., Tahir, N., Ijaz, S., Al-Kassas, R., & Löbenberg, R. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3cp55 · Cited by 176
“These polymerized liposomes are completely stable, provide modified release and enhance the half-life of therapeutic agents (186-188).”
BackgroundTargeting nanoparticles for diagnosis and therapy of bone tumors: Opportunities and challenges
Gao, X., Li, L., Cai, X., Huang, Q., Xiao, J., & Cheng, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120404 · Cited by 180
Li, S., Zhang, T., Xu, W., Ding, J., Yin, F., Xu, J., Sun, W. Y., Wang, H., Sun, M., Cai, Z., et al. (2018) · Theranostics · doi:10.7150/thno.18299 · Cited by 157
“For example, activated leukocyte cell adhesion molecule (ALCAM) was thought to be a biomarker of osteosarcoma, and the DOX-loaded anti-ALCAM diabody hybrid polymer liposomal nanoparticle (α-ALCAM-HPLN/DOX) offered more toxicity toward osteosarcoma cells than the non-targeted HPLN/DOX [34].”
Background
Metadata
- Authors
- Federman, N., Chan, J., Nagy, J. O., Landaw, E. M., McCabe, K., Wu, A. M., Triche, T., Kang, H., Liu, B., Marks, J. D., & Denny, C. T.
- Affiliations
- Mattel Children's Hospital (US)
- NanoValent Pharmaceuticals Inc., Bozeman, MT 59718-4012, USA
- University of California, Los Angeles (US)
- University of Southern California (US)
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA 90027, USA
- University of California, San Francisco (US)
- Corresponding author
- Federman, Noah
- Venue
- Sarcoma
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-11
- ISSN
- 1357-714X (ISSN-L)
- 1369-1643
- PMC
- PMC3447386
- OpenAlex
- W4213018315
- Cited by
- 44
- References
- 30
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 5
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Sarcoma (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
- National Science Foundation (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- osteosarcoma, ALCAM, ALDH1, cell surface receptors, liposomal doxorubicin, targeted drug delivery, immunoconjugates, cytotoxicity, tumor growth inhibition, bone cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.